Integra LifeSciences Reports Second Quarter 2024 Financial Results

Second Quarter 2024 Highlights Second quarter GAAP earnings per diluted share of $(0.16), compared to$0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to$0.71 in the prior year. Announced plans to focus relaunch of SurgiMend® and PriMatrix® at new state-of-the-art manufacturing facility in Braintree, Massachusetts, with operational readiness expected in the first-half of 2026. Updating full-year 2024 revenue guidance to a range of $1.609 billion to$1.629 billion and adjusted ...